Leerink Partners Initiates Coverage On Abivax with Outperform Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Thomas Smith has initiated coverage on Abivax (NASDAQ:ABVX) with an Outperform rating and set a price target of $20.
November 14, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abivax receives an Outperform rating from Leerink Partners with a price target of $20, indicating a positive outlook from the analyst.
Analyst ratings, especially initiations of coverage with positive outlooks, can influence investor sentiment and lead to short-term price increases. The Outperform rating and $20 price target suggest that Leerink Partners sees significant upside potential for Abivax, which could attract investor interest and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100